Interpretation of serum parathyroid hormone concentrations in dialysis patients: What do the KDIGO guidelines change for the clinical laboratory?

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 6, 2010, Pages 769-774

  Souberbielle, Jean Claude ^a   Cavalier, Etienne ^b   Jean, Guillaume ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Centre de Rein Artificiel de Tassin   (France)

Author keywords

Chronic kidney disease; Clinical guidelines; Dialysis; Parathyroid hormone; Reference values

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL LABORATORY; DATA ANALYSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HORMONE DETERMINATION; HUMAN; NORMAL VALUE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; RENAL OSTEODYSTROPHY; SHORT SURVEY; VITAMIN BLOOD LEVEL;

BLOOD CHEMICAL ANALYSIS; CALCIUM; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; PARATHYROID HORMONE; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC; REFERENCE VALUES; RENAL DIALYSIS;

EID: 77953207776     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.157     Document Type: Short Survey

References (31)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42: S1-201.
2. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;6:S1-130.
4. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993;43:436-442
5. Barretto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Dralbe SA, et al. K/DOQI-recommended intact PTH levels do not prevent low turnover bone disease in hemodialysis patients. Kidney Int 2008;73:771-777
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218
7. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
8. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-350
9. Mithal A, Wahl A, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009;20:1807-1820
10. Nussbaum S, Zahradnik R, Lavigne J, Brennan G, Nozawa- Ung K, Kim L, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-1367
11. Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Göhring U, et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab 1988;67:353-360
12. Endres D, Villanueva R, Sharp Jr C, Singer F. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991;37:162-168
13. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, et al. Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 2001;86:3086-3090
14. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340-350
15. Monge M, Jean G, Bacri JL, Masy E, Joly D, Souberbielle JC. Higher parathyroid hormone (PTH) concentrations with the architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods. Clin Chem Lab Med 2009;47:362-366
16. Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC. Vitamin D: current status and perspectives. Clin Chem Lab Med 2009; 47:120-127
17. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009;24:3799-3805
18. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Gao P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-761
19. Gao P, Scheibel S, D'Amour P, John M, Rao S, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-614
20. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai G, et al. PTH 1-84 and PTH ''7-84'' in the non-invasive diagnosis of bone disease. Am J Kidney Dis 2002;40:348-354
21. Salusky I, Goodman W, Kuizon B, Lavigne J, Zahranik R, Gales B, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63:1801-1808
22. Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman W. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005;68:1206-1214
23. Melamed M, Eustace J, Plantinga L, Jaar B, Fink N, Parekh R, et al. Third-generation parathyroid hormone assays and allcause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008;23:1650-1658
24. Souberbielle JC, Roth H, Fouque D. Parathyroid measurement in CKD. Kidney Int 2010;77:93-100.
25. Joly D, Drueke T, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987-995
26. Twoney PJ, Whitlock T, Pledger DR. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice. J Clin Pathol 2005;58:1000-1001
27. Holmes DT, Levin A, Forer B, Rosenberg F. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005;51:915-917
28. Glendenning P, Musk A, Taranto M, Vasikaran S. Preanalytical factors in the measurement of intact parathyroid hormone with the DPC Immulite assay. Clin Chem 2002;48:566-567
29. Cavalier E, Delanaye P, Carlisi A, Krzesinsky JM, Chapelle JP. Stability of parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007;72:370-372
30. Parent X, Alenabi F, Brignon P, Souberbielle JC. Delayed measurement of PTH in patients with CKD: storage of the primary tube in the dialysis unit, which temperature? Which kind of tube? warticle in Frenchx. Nephrol Ther 2009;5:34-40.
31. Cavalier E, Delanaye P, Hubert P, Krzesinski JM, Chapelle JP, Rozet E. Estimation of the stability of parathyroid hormone when stored at -808C for a long period. Clin J Am Soc Nephrol 2009;4:1988-1992